Oral Quercetin in Adult Patients as a Potential Nutraceutical against Coronavirus Disease 2019 (COVID-19)

Juan Fernando Ibarra Aguilar

ECOMED-LAMB Clinic, Asuncion, Paraguay.

Gabriela Ariane Sanabria Báez *

Instituto de Medicina Tropical, Asunción, Paraguay and Facultad de Ciencias Médicas, Universidad Nacional de Asunción – Filial Santa Rosa, Paraguay.

Fernando Galeano

Instituto de Medicina Tropical, Asunción, Paraguay and Facultad de Ciencias Médicas, Universidad Nacional de Asunción – Filial Santa Rosa, Paraguay.

*Author to whom correspondence should be addressed.


Abstract

Aim: To establishing the use of oral Quercetin as a potential nutraceutical against Coronavirus Disease 2019.

Methods: A descriptive, prospective longitudinal study was carried out on 52 patients treated at the ECOMED-LAMB Clinic, in the period from the onset of Covid-19 in our country, March 3, 2020 to January 2021.

Results: Were studied 52 patients COVID-19 positive, 20 (38.4%) were in preventive treatment and 32 patients (61.5%) was administered biological therapy once the diagnosis, no difference was found between female or male sex and the predominant age was those over 60 years. Twenty-four patients (70.6%) have presented at least one comorbidity.

The association of hospitalization with preventive treatment was not significant (p=0.166), we observed difference in the evolution of the patients (p= 0.084).

Conclusions: Quercetin could prevent and decrease the duration of SARSCoV-2 infections, it is plausible to propose the prophylactic use of this flavonoid in order to achieve clinical benefits.

Keywords: Clinical benefits, flavonoid, biological therapy, quercetin


How to Cite

Aguilar, Juan Fernando Ibarra, Gabriela Ariane Sanabria Báez, and Fernando Galeano. 2021. “Oral Quercetin in Adult Patients As a Potential Nutraceutical Against Coronavirus Disease 2019 (COVID-19)”. Journal of Advances in Medical and Pharmaceutical Sciences 23 (3):1-7. https://doi.org/10.9734/jamps/2021/v23i330222.

Downloads

Download data is not yet available.